Pioneering cellular medicines for women’s health

We’re developing off-the-shelf cell therapies for high-impact women’s diseases, with lead programs in ovarian cancer, triple negative breast cancer and endometriosis.

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers, endometriosis and Alzheimer’s disease. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer and beyond.

Learn more about us

Some of our partners

Latest news

Cartherics to present at the ISSCR 2025 Boston International Symposium

By Christine Filippis / December 8, 2025
Cartherics’ Deputy Chair, Prof. Alan Trounson AO will be presenting at ISSCR 2025 on Friday 12th December, 2025 at 3.25pm...
Read More

Launch of Evinco Therapeutics: A pioneering biotech company advancing immune therapies for Alzheimer’s disease

By Christine Filippis / December 4, 2025
Evinco Therapeutics is an Australian start-up on a mission to transform the treatment of Alzheimer’s disease and other neuroinflammatory conditions...
Read More

Cartherics appoints Dr Ian Nisbet as Chief Executive Officer

By Christine Filippis / November 28, 2025
  Dr Ian Nisbet appointed as Chief Executive Officer Prof Alan Trounson AO will move into the role of Deputy...
Read More
1 2 3 70